Treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) significantly reduces the risk of cardiovascular death or hospitalization ...
A statement from the makers of the SGLT2 inhibitor empagliflozin suggests the benefits in heart failure with preserved ejection fraction (HFpEF) are significant. For the first time, a clinical trial ...
The lack of approved treatments for heart failure with preserved ejection fraction has represented a significant unmet need for a condition that affects 50% of patients with heart failure, including ...
Patients with heart failure with preserved ejection fraction (HFpEF) -- a notoriously difficult population to treat -- had a meaningful reduction in cardiovascular death and heart failure ...
- The EMPEROR-Preserved Phase III trial met its primary endpoint and demonstrated significant risk reduction with empagliflozin for the composite of cardiovascular death or hospitalization for heart ...
(UPDATED) Full results of the EMPEROR-Preserved trial affirm that empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly) lowers the risk of CV death/hospitalization for heart failure in patients ...
Chronic kidney disease (CKD) had no impact on the efficacy or safety of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance, Boehringer Ingelheim) for patients with heart ...
- The positive opinion is based on the landmark EMPEROR-Preserved Phase III trial, which showed significant outcomes in patients with heart failure with left ventricular ejection fraction over 40% 1 - ...
Lungs Heart The phase 3 EMPEROR-Preserved trial assessed empagliflozin in 5988 adults with heart failure with preserved ejection fraction, with and without diabetes. Full results from the phase 3 ...
Please provide your email address to receive an email when new articles are posted on . Anticipated results of the EMPEROR-Preserved trial demonstrate that the SGLT2 inhibitor empagliflozin improved ...
The EMPEROR-Preserved trial of empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly) met its primary endpoint, according to top-line results released today, meaning a therapy with specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results